相关实验视频

Updated: Jul 13, 2025

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

通过下一代RNA和全转录组测序检测到的ROS1融合的泛瘤调查

Misako Nagasaka^1,2,3, Shannon S Zhang⁴, Yasmine Baca⁵

¹Department of Medicine, Division of Hematology and Oncology, University of California Irvine School of Medicine, 200 South Manchester Ave, Orange, CA, 92868, USA. nagasakm@hs.uci.edu.

|October 18, 2023

概括

这项研究在各种固体瘤中确定了ROS1融合,非小细胞肺癌是最常见的. 综合的基因组分析可能有助于确定更多符合ROS1氨酸激酶抑制剂治疗的患者.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
精准医学是一门精准的医学.

背景情况:

两种ROS1氨酸激酶抑制剂 (TKI) 已被批准用于ROS1融合阳性 (ROS1+) 非小细胞肺癌 (NSCLC).
进行了全瘤分析,以确定更多可能受益于ROS1TKI的ROS1+患者.

研究的目的:

为了评估ROS1融合在各种固体瘤类型中的发生率.
确定ROS1 TKIs在NSCLC之外的更广泛应用的潜力.

主要方法:

对ROS1+固体恶性瘤的回顾性分析.
利用临床瘤样本的向RNA测序和整个转录组测序.

主要成果:

从约175,350个瘤中确定了259种ROS1+固体恶性瘤.
ROS1+NSCLC占78.8%的病例,其次是质母细胞瘤 (6.9%) 和乳腺癌 (2.7%).
在NSCLC中,ROS1融合频率为0.47%,在GBM中为0.29%,在乳腺癌中为0.04%.

结论:

ROS1+ NSCLC是ROS1融合的主要恶性瘤.
超过20%的ROS1+固体瘤可能受益于ROS1TKI治疗.
建议对所有固体瘤进行全面的基因组分析,以确定ROS1 TKI治疗的潜在候选人.

关键词:

乳腺癌乳腺癌乳腺癌非小细胞肺癌是非小细胞肺癌.泛瘤分析泛瘤分析受体氨酸激酶融合的受体.在 c-ROS1 中,

更多相关视频

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations

Published on: August 4, 2016

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

相关概念视频